News and Trends 10 Aug 2022
GentiBio and Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases
GentiBio, Inc. has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cells (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). The collaboration brings together GentiBio’s engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb’s […]